UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

Alistair J Roddick; Alexa Wonnacott; David Webb; Angela Watt; Michael A Watson; Natalie Staplin; Alex Riding; Eirini Lioudaki; Apexa Kuverji; Mohsen El Kossi; Patrick Holmes; Matt Holloway; Donald Fraser; Chris Carvalho; James O Burton; Sunil Bhandari; William G Herrington; Andrew H Frankel

doi:10.1186/s12882-023-03339-3

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

BMC Nephrol. 2023 Oct 25;24(1):310. doi: 10.1186/s12882-023-03339-3.

Authors

Alistair J Roddick^{1

2}, Alexa Wonnacott³, David Webb⁴, Angela Watt⁵, Michael A Watson⁵, Natalie Staplin¹, Alex Riding⁶, Eirini Lioudaki⁷, Apexa Kuverji⁸, Mohsen El Kossi⁹, Patrick Holmes¹⁰, Matt Holloway¹¹, Donald Fraser³, Chris Carvalho^{12

13}, James O Burton¹⁴, Sunil Bhandari¹⁵, William G Herrington^#^{1

2}, Andrew H Frankel^#¹⁶

Affiliations

¹ The Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK.
² Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
³ Wales Kidney Research Unit, Cardiff University, Cardiff, UK.
⁴ Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK.
⁵ UKKA Patient Representative, Bristol, UK.
⁶ Royal Free London NHS Foundation Trust, London, UK.
⁷ Kings College Hospital NHS Trust, London, UK.
⁸ John Walls Renal Unit, Glenfield Hospital, Leicester, UK.
⁹ Doncaster Royal Infirmary, Doncaster, UK.
¹⁰ Primary Care Diabetes Society, Darlington, UK.
¹¹ East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.
¹² North East London Integrated Care Board, London, UK.
¹³ Clinical Effectiveness Group, Queen Mary University of London, London, UK.
¹⁴ Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
¹⁵ Hull University Teaching Hospitals NHS Trust and Hull York Medical School, Hull, UK.
¹⁶ Imperial College Healthcare NHS Trust, London, UK. a.frankel@imperial.ac.uk.

^# Contributed equally.

Abstract

Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full "lay" summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.

Keywords: Acute kidney injury; Chronic kidney disease; Gliflozin; Guideline.

Publication types

Practice Guideline
Review

MeSH terms

Adult
Blood Glucose
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Kidney
Kidney Diseases*
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
United Kingdom

Substances

Blood Glucose
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding